Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.

× No keyword cloud information.

21 in total

1. Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors: J Kuhlmann; V Kötter; N Rietbrock
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1977-06 Impact factor: 3.000

2. Canrenone--the principal active metabolite of spironolactone?

Authors: L E Ramsay; J R Shelton; D Wilkinson; M J Tidd
Journal: Br J Clin Pharmacol Date: 1976-08 Impact factor: 4.335

3. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.

Authors: W Sadée; U Abshagen; C Finn; N Rietbrock
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1974 Impact factor: 3.000

4. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

Authors: W Sadée; R Schröder; E von Leitner; M Dagcioglu
Journal: Eur J Clin Pharmacol Date: 1974 Impact factor: 2.953

5. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience.

Authors: G T McInnes; J R Shelton; L E Ramsay; I R Harrison; M J Asbury; J M Clarke; R M Perkins; G R Venning
Journal: Br J Clin Pharmacol Date: 1982-03 Impact factor: 4.335

10. Effects of aldosterone and potassium-sparing diuretics on electrical potential differences across the distal nephron.

Authors: J B Gross; J P Kokko
Journal: J Clin Invest Date: 1977-01 Impact factor: 14.808

Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.

1. Canrenoate disposition in dogs. Tissue distribution and elimination.

2. Canrenone--the principal active metabolite of spironolactone?

3. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.

4. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

5. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience.

6. Improved method for comparative evaluation of aldosterone antagonists in healthy man.

7. Spironolactone. An aldosterone agonist in the stimulation of H+ secretion by turtle urinary bladder.

8. Induction of citrate synthase by aldosterone in the rat kidney.

9. Spironolactone antagonism of aldosterone action on Na+ transport and RNA metabolism in toad bladder epithelium.

10. Effects of aldosterone and potassium-sparing diuretics on electrical potential differences across the distal nephron.